Background and purpose
======================

Several new anti-cancer drugs have recently entered clinical practice in oncology. Among those, especially targeted drugs are promising therapeutic candidates with a comparatively low toxicity profile. At present, these drugs are often applied in palliative treatment situations for metastasized diseases. In addition, targeted agents are a substantial part of many multimodal oncologic treatment schedules. Thus the risk of parallel use of both radiotherapy and targeted drug is given. With few exceptions, the toxicity of any combination of targeted drugs with radiotherapy has not yet been studied in detail.

Key cellular signalling pathways \[[@B1]\] are responsible for the response of normal tissue and tumour cells to radiation therapy \[[@B2]\]. Although some of the anti-cancer targets are specific for neoplastic signalling, there is considerable overlap between neoplastic signalling and normal cellular signalling. In this regard, several putative interactions with radiation triggered signalling in normal issues exist and thus \[[@B3],[@B4]\] influences of targeted drugs on normal tissue reactions cannot be excluded \[[@B5]-[@B7]\].

The present article reviews the existing data on the toxicity profile and efficacy (if available) of targeted drugs when applied concurrently to radiotherapy.

Methods and materials
=====================

Using the following MESH headings and combinations of these terms, pubmed database was searched for randomized, prospective and retrospective trials as well as case reports (all sample sizes were considered):

1\. Radiotherapy AND cetuximab/trastuzumab/panitumumab/nimotuzumab

2\. Radiotherapy AND bevacizumab

3\. Radiotherapy AND sunitinib/sorafenib/lapatinib/gefitinib/erlotinib/sirolimus

4\. Radiotherapy AND thalidomide/lenalidomide.

5\. Radiotherapy AND erythropoietin

For citation crosscheck, the ISI web of science database was used employing the same search terms. A focus was put on prospective or phase I/II trials; if available, some smaller case studies or case reports were included if higher toxicities were reported.

In general, grade III + IV toxicities are reported. For cetuximab, focus was set on larger phase III trials and those reporting trials specifically reporting toxicities. In addition, key reviews focusing on the use of targeted drug in oncology were screened in order to identify clinically relevant drugs \[[@B8]\].

Results
=======

Antibodies
----------

### Cetuximab

Cetuximab is a monoclonal chimeric antibody directed against the epidermal growth-factor receptor (EGF-R). It has first been approved for treatment of locally advanced or metastatic colorectal cancer (k-ras wildtype) refractory to irinotecan \[[@B9]\]. Regarding radiotherapy, it has been approved for head-and-neck cancer as an alternative to concomitant chemotherapy \[[@B10]\]; in the given phase III trial overall survival of patients who were treated by radiotherapy and cetuximab was improved compared to patients who underwent radiotherapy alone. Cetuximab also has a proven efficacy in locally advanced or metastatic head-and-neck cancer in combination with 5-FU/cisplatin \[[@B11]\].

Thus several pre-clinical and clinical studies have provided evidence for the efficacy of cetuximab in combination with radiotherapy \[[@B12]-[@B17]\]. Nevertheless, several reports are available pointing to increased skin toxicity after combining cetuximab with radiotherapy \[[@B18]-[@B27]\] (a complete overview is given in Table [1](#T1){ref-type="table"}). The initial publication on the combined use by Bonner and colleagues reported an increased incidence of an acneiform rash \[[@B10]\]. However, in single cases more severe complications occurred \[[@B19]\]. A recent retrospective matched-pair evaluation of acute toxicity during cis-platinum-based radio-chemotherapy versus radiotherapy with simultaneous cetuximab treatment showed significantly higher grade 3 oral mucositis and dermatitis as well as a higher risk of weight loss (\> 10%) and of enteral feeding requirement in the cetuximab-group. However, this may be outweighed by the higher risk of haematological toxicity by radio-chemotherapy. In keeping with this, higher compliance rate with less treatment interruptions in the cetuximab-treated group was described \[[@B26]\]. In trials on thoracic \[[@B28],[@B29]\] or pelvic radiotherapy with cetuximab increased rates of skin toxicity were not observed.

###### 

Studies on monoclonal EGFR antibodies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substance            Author(s)                                Year   Study type                   N                                 Tumour                            RT dose/ChTx/technique                                                    Toxicity
  -------------------- ---------------------------------------- ------ ---------------------------- --------------------------------- --------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cetuximab            Bonner et al. \[[@B10]\]                 2006   Phase III                    211 (cetux-arm)                   LA-HNSCC                          70-78.8 Gy (hyper-fractionated)                                           Significant differences or trend in arms: 8% grade III-V acneiform rash, 1% grade III-V voice alteration, 1% grade III-V infusion reaction

                       Koutcher et al. \[[@B24]\]               2009   Retrospective                115                               LA-HNSCC                          66 Gy/69.96 Gy                                                            3% grade IV radio-dermatitis, 19% grade III radio-dermatitis

                       Studer et al. \[[@B25]\]                 2011   Prospective                  99                                HNSCC                             66-70 Gy, 30/99 switch from Cis                                           34% grade II/IV dermatitis

                       Hallqvist et al. \[[@B28]\]              2010   Phase II                     75                                NSCLC                             68 Gy, Ind. ChTx Doc/Cis + concomitant Cetux                              1% grade V pneumonitis, 4% grade III pneumonitis, 5% grade III + IV hypersensitivity, 15% grade III + IV febrile neutropenia, 4% III skin reactions

                       Jensen et al. \[[@B122]\]                2010   Retrospective                73                                HNSCC                             22 pts Re-RT (50-60 Gy), 66-70 Gy                                         5% grade III allergic reaction, 4% grade III acneiform rash

                       Garcia-Huttenlocher et al. \[[@B123]\]   2009   Retrospective                65                                HNSCC                             Median 66 Gy (IMRT)                                                       Grade III: skin toxicity 28%, mucositis 25%

                       Rödel et al. \[[@B115]\]                 2008   Phase I/II                   12/48                             Rectal cancer                     50,4 Gy +Capecitabine + Oxaliplatin                                       Phase II only Grade IV/V: Leukopenia, thrombocytopenia, Diarrhea, Creatinine elevation, e-lyte derivation, infection each 2%

                       Safran et al. \[[@B31]\]                 2008   Phase II                     60                                Esophago-gastric-cancer           Cetux/Carbo/Tax + 50.4 Gy                                                 23% grade III rash, 15% grade III/IV esophagitis, 5% III + IV hypersensitivity, 3% grade IV neutropenia (10% grade III), 2% IV anemia (8% grade III)

                       Jatoi et al. \[[@B124]\]                 2010   Phase II                     57                                NSCLC                             60 Gy                                                                     2% grade IV each: dysphagia/hypomagnesemia/dyspnea/headache/thrombosis/GI hemorrhage, 7% grade III rash

                       Horisberger et al. \[[@B30]\]            2009   Phase II                     50                                Rectal cancer                     50,4 Gy + Capecitabine + Irinotecan                                       Leukopenia 4% grade III and IV each\
                                                                                                                                                                                                                                                  Grade III: Diarrhea 60%, abdominal pain 8%, ALAT/ASAT elevation 20%, Acneiform skin rash 12%, anemia, nausea/vomiting, bilirubin elevation, proctitis each 4%

                       Koutcher et al. \[[@B125]\]              2011   Retrospective                49                                LA-HNSCC                          69.96 Gy (IMRT) (comparison vs. concomitant Cis)                          20% late grade III + IV toxicity

                       Walsh et al. \[[@B26]\]                  2011   Retrospective                48 (14 excluded because of SIB)   HNSCC                             Cis vs. Cetux (66-70 Gy)                                                  44% ≥ grade III skin toxicity, 52% ≥ grade III mucositis, 6% ≥ grade III acneiform rash

                       Buiret et al. \[[@B126]\]                2010   Retrospective multicenter    46                                HNSCC                             Ind. ChTx Doc/Cis/5-FU, RIT (70 Gy)                                       No grade IV toxicity

                       Garcia-Huttenlocher et al. \[[@B127]\]   2008   Retrospective                46                                HNSCC                             Median 66 Gy (IMRT)                                                       20% grade III skin toxicity, 4% grade III mucositis

                       Merlano et al. \[[@B128]\]               2010   Phase II                     45                                HNSCC                             Up to 70 Gy, three cycles Cis/5-FU, split course RT, RT + cetux           2% grade IV leukopenia (38% grade III), 7% grade IV neutropenia (33% grade III), 2% grade IV thrombopenia (13% grade III), 36% grade IV stomatitis (29% grade III), 73% grade III radiodermatitis, 7% grade III rash

                       Koukourakis et al. \[[@B60]\]            2010   Phase I                      43                                LA-HNSCC                          21 × 2.7 Gy (56.7 Gy) + amifostine + Cis                                  16% grade III + IV mucositis, 2% grade III + IV skin toxicity

                       Suntharalingam et al. \[[@B129]\]        2011   Phase II                     43                                LA-HNSCC                          70,2 Gy (3D/IMRT) + Paclitaxel, Carboplatin,                              Grade 3 mucositis (79%), rash (9%), leukopenia (19%), neutropenia (19%), and RT dermatitis (16%)

                       De Vita et al. \[[@B130]\]               2011   Phase II                     41                                Esophageal cancer                 Ind. FOLFOX4 + 50.4 Gy/Cetux                                              30% grade II/IV skin toxicity/neutropenia

                       Bertolini et al. \[[@B117]\]             2009   Phase II                     40                                LA rectal cancer                  50-50.4 Gy + neoadj. Cetux/Cetux + 5-FU concomitant                       8% grade III/IV skin rash, 8% grade III/IV hypersensitivity, 13% grade III/IV GI toxicity, 3% grade III/IV febrile neutropenia

                       Kim et al. \[[@B98]\]                    2011   Phase II                     40                                Rectal cancer                     Capecitabine + Cetux + Irinotecan + 50.4 Gy                               3% grade IV leukopenia, 3% grade III rash

                       Machiels et al. \[[@B119]\]              2007   Phase I/II                   40                                Rectal cancer                     45 Gy + Capecitabine                                                      3% grade III/IV allergic reaction, 3% grade III/IV dermatitis

                       Argiris et al. \[[@B131]\]               2010   Prospective                  39                                LA-HNC                            Induction Docetaxel/Cis/Cetux + concurrent Cisplatin/Cetux/70-74 Gy-RT    Grade III/IV: oral mucositis 46%, Anemia 21%, in-field dermatitis 23%, Dysphagia 41%, Thrombocytopenia 10%, Neutropenia 31%, febrile neutropenia 5%, infection 18%, fatigue 13%, nausea 10%, vomiting 3%, renal failure 3%, DVT 5%, bleeding 5%.

                       Velenik et al. \[[@B118]\]               2010   Phase II                     37                                Rectal cancer                     45 Gy RT + capecitabine (neoadjuvant)                                     Grade III: diarrhea 11%, anorexia 3%, hepatotoxicity 3%, in-field-dermatitis 16%, infection 3%, hypersensitivity 5%.

                       Heron et al. \[[@B132]\]                 2011   Matched pair retrospective   35                                HNSCC                             SBRT Re-RT                                                                No significant increase grade III + IV

                       Birnbaum et al. \[[@B133]\]              2010   Phase I                      32                                LA-HNSCC                          66-72 Gy, Ind. Cetux + Carbo/Tax/Cetux concomitant                        3% grade III allergic reaction, 3% grade IV metabolic symptom, 69% grade III + IV mucositis, 3% grade IV dysphagia, 59% pts grade III + IV skin toxicity

                       Jensen et al. \[[@B134]\]                2011   Phase II                     30                                NSCLC                             66 Gy (IMRT)                                                              Pulmonary embolism 3% grade III + 3% grade V endocarditis and myocardial infarction grade V each 3%, 13% grade III/IV pneumonia esophagitis, diarrhea, DVT, exacerbation of COPD, urosepsis, pericardial effusion, pneumonitis grade III each 3%

                       Ruhstaller et al. \[[@B135]\]            2011   Phase IB/II                  28                                Esophageal cancer                 Induction ChTx Cis/docetaxel + neoadjuvant RCh-immunotherapy              25% grade III/IV esophagitis, 4% grade III/IV rash

                       Pfister et al. \[[@B136]\]               2006   Phase I                      22                                LA-HNSCC                          70 Gy RT + Cisplatin                                                      Study closed due to significant AEs.\
                                                                                                                                                                                                                                                  Grade V pneumonia and one death of unknown cause,\
                                                                                                                                                                                                                                                  Grade IV: MI 5%, arrhythmia 5%, metabolic 5%, infection 5%

                       Hofheinz et al. \[[@B137]\]              2006   Phase I                      20                                Rectal cancer                     Capecitabine + Irinotecan + 50.4 Gy                                       No grade IV, no rash, 20% grade III diarrhea

                       Kuhnt et al. \[[@B138]\]                 2010   Phase I                      18 (16 eligible)                  LA-HNSCC                          HART (70.6 Gy) + Cis                                                      56% grade III mucositis, 38% ≥ grade III radiodermatitis, 25% ≥ grade III neutropenia, 6% grade III rash

                       Pryor et al. \[[@B22]\]                  2009   Prospective                  13                                HNSCC                             70 Gy                                                                     46% ≥ grade III acneiform rash, 77% ≥ grade III dermatitis

                       Hughes et al. \[[@B29]\]                 2008   Phase I                      12                                NSCLC                             64 Gy                                                                     Grade III fatigue, pneumonitis each 8%\
                                                                                                                                                                                                                                                  Grade V Infection 8%

                       Zwicker et al. \[[@B139]\]               2011   Phase II                     10                                HNSCC                             IMRT 50.4 Gy Re-RT + Cetux                                                10% grade V mucositis, 10% grade III mucositis, 10% grade IV erythema (20% grade III), 20% grade III acneiform rash

                       Jensen et al. \[[@B140]\]                2010   prospective                  9                                 Adenoid cystic carcinoma of HN    5/9: re-RT: median 50,4 Gy, median 65 Gy otherwise (IMRT or C-12 boost)   Grade III Mucositis and Grade III Dysphagia

                       Balermpas et al. \[[@B141]\]             2009   Prospective                  7                                 HNSCC                             Re-irradiation 50,4 Gy-54,0 Gy                                            New acute side effects:\
                                                                                                                                                                                                                                                  Grade III: pain 14%, mucositis 71%. Dysphagia 57%. Xerostomia 14%. Fibrosis 14%, acneiform rash 29%.

                       Berger et al. \[[@B19]\]                 2008   Case report                  1                                 HNSCC                             72 Gy., regimen change to cetuximab from 5-FU/MMC                         Grade IV Dermatitis

  Trastuzumab          Halyard et al. \[[@B48]\]                2009   Phase III                    1503                              Breast cancer                     Median 50,4 Gy, previous OP + ChTx                                        Skin toxicity grade III: 4% (simultaneous) -6% (adjuvant), cardiac events 2% (simultaneous)-3% (adjuvant)

                       Belkacemi et al. \[[@B49]\]              2008   Multicentric study           146                               Breast cancer                     Median 50 Gy                                                              \> grade II esophagitis (12%), 1 pt grade III esophagitis, 5% grade III dermatitis, ≥ grade II LVEF (10%)

                       Caussa et al. \[[@B142]\]                2011   Prospective                  106                               Breast cancer                     50 Gy (2 Gy) + 16 Gy boost                                                2% grade III skin reaction, 1% grade III esophagitis

                       Anderson \[[@B143]\]                     2009   Matched case control study   85                                Breast cancer                     n\. r.                                                                    Grade III dermatotoxicity 2%, 1% ≥ grade II LVEF decrease (reversible)

                       Shaffer et al. \[[@B50]\]                2009   retrospective                44                                Breast cancer                     40-50.4 Gy                                                                In 14% stopped because of cardiac toxicity

                       Chargari et al. \[[@B144]\]              2011   Phase I                      31                                Brain mets breast cancer          30 Gy (3 Gy) WBRT                                                         No grade \> II

                       Horton et al. \[[@B145]\]                2010   Phase II                     12                                Locally recurrent breast cancer   50 Gy, ChTx refractory                                                    17% grade III skin toxicity, 8% grade III lymphopenia, no cardiac toxicity

  Panitumumab          Pinto et al. \[[@B35]\]                  2011   Phase II                     60                                Rectal cancer                     5-fluorouracil-oxaliplatin + RT                                           Grade 3-4 toxicity: diarrhea (39%, one toxic death), cutaneous reactions (19%), nausea, neutropenia (2%), others.

                       Wirth et al. \[[@B34]\]                  2010   Phase I                      19                                LA-HNSCC                          70 Gy + Carbo/Tax (2 Gy) IMRT                                             1 pt grade III febrile neutropenia, 84% grade III + IV mucositis, 95% grade III dysphagia, 42% grade III dermatitis, 11% grade III rash, 21% grade III nausea

  Nimotuzumab (h-R3)   Rodriguez et al. \[[@B38]\]              2010   Prospective randomized       106                               HNSCC                             n\. r.                                                                    III/IV not reported

                       Crombet et al. \[[@B146]\]               2004   Phase I                      24                                HNSCC                             66 Gy (2 Gy)                                                              4% grade III somnolence, 13% grade III dysphagia, 21% grade III mucositis, 13% grade III dermatitis, 4% grade III laryngitis

                       Bebb et al. \[[@B39]\]                   2011   Phase I                      18                                NSCLC                             36/30 Gy (3 Gy)                                                           50% grade III + IV

                       Choi et al. \[[@B40]\]                   2010   Phase I                      15                                NSCLC                             36/30 Gy (3 Gy)                                                           7% grade IV febrile neutropenia/pneumonia, 40% grade III lymphopenia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, HCC-hepatocellular carcinoma, RCC-renal cell cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis, Fx-fractions, SRS-stereotactic radiosurgery, DLT-dose limiting toxicity, LA-locally advanced, Gem-gemcitabine, Tax-Taxol (paclitaxel), Tx-therapy, TMZ-temozolomide, PCP-Pneumocystis pneumonia, Cis-cisplatin, Eto-etoposide, Doc-docetaxel

No other risks regarding additional or increased side effects concerning connective tissue, CNS \[[@B30]-[@B32]\] or peripheral nerves have been described so far in small early-phase clinical trials.

### Panitumumab

Similar to cetuximab, panitumumab is a monoclonal antibody directed against EGF-R with a putatively higher affinity and less toxicity due to its non-chimeric design. It has been approved for stage IV colorectal cancer refractory to FOLFOX or FOLFIRI \[[@B33]\].

Only data from a single phase I study \[[@B34]\] and a single phase II trial described effects of a combination of panitumumab with a 5-FU/oxaliplatin-containing radio-chemotherapy for rectal cancer \[[@B35]\]. Pre-clinical data suggest a comparable efficacy to cetuximab \[[@B36]\]. Concerning toxicity, no additional toxicity was observed when combined with radiotherapy. The phase II trial reported one toxic death from diarrhea and a relatively high rate of grade III/IV diarrhea (39%) compared to the classical CAO/ARO/AIO-94 trial \[[@B37]\]. However, based on the design of the trial it is not possible to precisely attribute the side effects to any of the components of the given protocol.

### Nimotuzumab

Nimotuzumab is another humanized therapeutic monoclonal antibody directed against EGF-R not yet been approved by the authorities in Europe. There are three small phase I trials testing radiotherapy and nimotuzumab in head-and-neck cancer as well as NSCLC patients; an increased rate of skin toxicity was observed \[[@B38]-[@B40]\]. The other larger phase II trial by Rodríguez and colleagues was prospectively randomized and 106 head-and-neck cancer patients were included \[[@B38]\]. No grade III or IV toxicity has been observed.

The data available suggest that the combination of cetuximab with radiation may lead to an increased rate of mucosal- and skin toxicity when applied together with radiation for the treatment of head-and-neck cancer. No such problems have been reported in other organ regions. It is unclear in how far this is an epitope-specific side effect-only limited data are available regarding similar effects after the combined use of panitumumab and nimotuzumab.

Anti -Her2/neu antibody trastuzumab
-----------------------------------

Trastuzumab is a humanized monoclonal antibody directed against the epidermal growth-factor-receptor Her-2/neu. It is approved for the treatment of metastatic her-2/neu-positive breast cancer as well as for the adjuvant treatment of her-2/neu-positive breast cancer in combination with chemotherapy \[[@B41]-[@B44]\].

Cardiac toxicity is a rare, but well described adverse effect of trastuzumab-especially with or after the treatment with anthracyclins \[[@B45]-[@B47]\]. As cardiac toxicity is also of concern in thoracic radiotherapy, the question of an increased toxicity has been raised. The largest trial focusing on side effects of the combined use of radiotherapy and trastuzumab is the phase III NLCCTG trial N9831 for adjuvant trastuzumab and radiotherapy including 1503 patients \[[@B48]\]. The trial did not reveal any significant differences in toxicity regarding skin, pneumonitis or cardiac events. Also, a French multicentric study \[[@B49]\] including 146 patients did not observe an increased cardiac toxicity. Another study retrospectively investigated the combinational approach of trastuzumab and radiotherapy including the internal mammary lymph nodes \[[@B50]\]. Again, no increased cardiac toxicity has been observed.

Thus, at present there are no strong indicators for an increased cardiac toxicity. However, follow-up periods are only sufficient for an estimation of early cardiac toxicity caused by trastuzumab, but not for an in-depth assessment of late radiation-induced cardiac effects.

Altogether, the current data suggest that the use of trastuzumab in a close time frame with radiotherapy may be safe. However, the reported studies might still reveal an increased cardiac toxicity, as minor vascular changes might lead to an increased mortality in long-term follow-up \[[@B51]\].

Bevacizumab
-----------

Bevacizumab is a humanized monoclonal antibody against the vascular endothelial growth-factor (VEGF). So far, bevacizumab has been approved for the treatment of metastatic colorectal carcinoma, in combination with standard chemotherapy (5-FU, irinotecan, oxaliplatin or capecitabine). Bevacizumab has been approved for the treatment of metastatic non-squamous-cell bronchial carcinoma, for the treatment of renal cell cancer and for the treatment of glioblastoma multiforme (US only). The FDA has withdrawn the approval for first line treatment of metastatic HER-2/neu-negative breast cancer-however, the drug still is approved in Europe.

The most common side effects of bevacizumab alone include impaired wound healing, hypertension, bleeding problems as well as an increased risk of thromboembolic events.

One of the first publications to describe an increased risk of combining bevacizumab with radiotherapy reported on patients with ischemic bowel complications after the administration of radiotherapy followed by bevacizumab \[[@B52]\].

A phase II study combining neoadjuvant bevacizumab, capecitabine and radiotherapy for locally advanced rectal cancer revealed an increased rate of wound complications such as delayed healing and wound dehiscence \[[@B53]\]. The data are in line with a number of similar reports and case studies, supporting the interpretation that the combined use of bevacizumab with neoadjuvant radiotherapy is associated with an increased risk of postoperative complications \[[@B54]-[@B57]\]. However, this interpretation is not homogenously supported by all available data \[[@B58]-[@B61]\]. In terms of tumour response, the rate of pathological complete responses seems to be enhanced \[[@B53]\].

The use of bevacizumab, capecitabine and radiotherapy in patients with locally advanced pancreatic cancer was associated with an increased rate GI-bleeding and ulcerations (12%) \[[@B62]\]. These complications preferentially occurred in patients with a mucosal infiltration of the tumour. In a consecutive study -after excluding patients with mucosa infiltration-no such side effects were reported \[[@B63]\]. A similar study reported the combination of radiotherapy with bevacizumab-partly in a neoadjuvant setting- as \"feasible\" \[[@B64]\].

The combination of radiotherapy with simultaneous administration of bevacizumab was also tested for lung cancer \[[@B65],[@B66]\]. In this setting, the occurrence of severe fistula leading to a discontinuation of both trials has been described \[[@B66]\].

In case of breast cancer the parallel combination of radiotherapy and bevacizumab had no significant side-effects in regard to lung and skin toxicity \[[@B65]\].

The treatment of malignant tumours of the brain has been subject to a variety of studies combining radiotherapy with bevacizumab with or without temozolomide; regarding progression-free survival, these trials suggest a benefit of the combined use \[[@B67]\]. No intra-cerebral bleeding has been reported, however cases of wound dehiscence of the previous operation have been documented \[[@B68]-[@B70]\]. A collection of case reports points towards increased late toxicity such as optic neuropathy and a single case of Brown-Séquard syndrome after a combination of bevacizumab with radiotherapy \[[@B71]\]. (a complete overview is given in Table [2](#T2){ref-type="table"}).

###### 

Studies on VEGF antibodies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substance     Author(s)                        Year   Study type      N          tumour                            RT dose/ChTx/technique                                                Toxicity
  ------------- -------------------------------- ------ --------------- ---------- --------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bevacizumab   Vredenburgh et al. \[[@B147]\]   2010                   125        Glioblastoma                      59,4 Gy/Temozolomide                                                  Grade III Thromboembolic events: 2%

                Crane et al. \[[@B63]\]          2009   Phase II        82         Pancreatic Cancer                 50,4 Gy/Capecitabine                                                  Toxicities possibly attributable to bevacizumab: GI bleeding: 6%. (d83,127,179, 180, 316); grade III, IV, V GI perforation: 4%. (d195,231,286)\
                                                                                                                                                                                           DVT grade III + IV: 4%; grade III hypertension: 2%;

                Lai et al. \[[@B72]\]            2010   Phase II        70         Glioblastoma                      60 Gy/Temozolomide                                                    Grade IV cerebrovascular ischemia: 9%; Grade III+IV CNS hemorrhage: 3%; Grade III+IV GI bleeding/perforation 6%; grade IIII Optic neuropathy: 1%. Grade III+IV venous Thrombosis/PE: 19%.

                Crane et al. \[[@B62]\]          2006   Phase I         48         Pancreatic Cancer                 50,4 Gy/Capecitabine                                                  Toxicities possibly attributable to bevacizumab: grade III+V ulceration with bleeding in RT field: 8%. (retrospectively fistulous connection identified in 4%)\
                                                                                                                                                                                           Grade III GI perforation: 4%; bleeding outside field): 4%; grade III hypertension: 2%.

                Seiwert et al. \[[@B148]\]       2008   Phase I         43         Head & Neck                       63-72 Gy/5-FU and Hydroxyurea                                         Grade V bleeding events: 5%; grade V infection/sepsis: 7%, 2% unknown cause of death; grade III+ Thromboembolic events: 5% DVT, 2% stroke (leading to fatal sepsis, see above); fistula (due to radionecrosis or residual tumour): 12%. Tissue necrosis 9%.

                Spigel et al. \[[@B149]\]        2009   Phase II        A 29 B 5   SCLC                              61,2 Gy/Carboplatin/Irinotecan (A-limited stage B-locally advanced)   A Grade IV+V tracheoesophageal fistula: 7%. Grade V aerodigestive hemorrhage. B Grade III tracheoesophageal fistula: 40%. Both studies closed due to toxicity.

                Willet et al. \[[@B58]\]         2009   Phase II        32         Rectal Cancer                     50,4 Gy//5-FU                                                         Grade III toxicities: GI abscess 3%, Hypertension 9%, radiation dermatitis: 6%; wound separation 3%. No grade IV.

                Dipetrillo et al. \[[@B55]\]     2012   Phase I         26         Rectal Cancer                     50,4 Gy/FOLFOX                                                        Grade III + IV Diarrhea: 42%; Bleeding (g3): 4%; g3 neuropathy: 4%; Radiation dermatitis G3: 8%; postoperative wound complications: 35%-the study was discontinued due to this toxicity.

                Crane et al. \[[@B53]\]          2010   Phase II        25         Rectal Cancer                     50,4 Gy/Capecitabine                                                  grade III perianal desquamation: 4%; 12% major surgical complications such as anastomotic dehiscence (4%), wound dehiscence (8%)

                Gutin et al. \[[@B68]\]          2009   Phase I         25         Glioblastoma/Anaplastic Gliomas   30 Gy/5 × 6 Gy                                                        Grade IV Gastrointestinal bleeding: 4%, bowel perforation: 4%, wound healing complication: 4%. Grade III CNS hemorrhage: 4%.

                Koukourakis et al. \[[@B59]\]    2009   Phase I/II      22         Rectal Cancer                     15 × 3,4 Gy/amifostine, capecitabine                                  Fistula: 9%, grade IV skin necrosis 5%.

                Niyazi et al. \[[@B69]\]         2010   Retrospective   20         Recurrent Glioblastoma            36 Gy                                                                 Grade IV wound healing complication: 5%. grade III DVT: 5%.

                Koukourakis et al. \[[@B150]\]   2011   Phase II        19         Rectal cancer                     10 × 3, 4 Gy Amifostine/Capecitabine                                  Grade III diarrhea: 11%.

                Goyal et al. \[[@B65]\]          2010   Retrospective   14         Breast cancer                     50 Gy + 10 Gy                                                         No Grade III/IV toxicity (only acute toxicity assessed)

                Czito et al. \[[@B61]\]          2007   Phase I         11         Rectal Cancer                     50,4 Gy/Oxaliplatin + Capecitabine                                    No grade III + toxicities attributable to bevacizumab: grade III-IV diarrhea: 27%,

                Resch et al. \[[@B151]\]         2011   Phase II        8          Rectal cancer                     45 Gy/Capecitabine                                                    Discontinued due to tox after 8 Pt., Grade III GI bleeding: 25%, Grade III diarrhea: 25%

                Kelly et al. \[[@B71]\]          2010   Case reports    3          Glioblastoma                                                                                            Optic neuropathy

                Vargo et al. \[[@B152]\]         2011   Case report     1          Glioblastoma                                                                                            Dural venous thrombosis
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N-number of patients

Altogether, the combined use of bevacizumab and radiotherapy seems to be associated with a considerable risk of side effects (wound dehiscence, bleeding, fistula or GI complications). However, in selected cases the combination was feasible and even favourable concerning overall survival (retrospective) \[[@B69]\] and progression-free survival \[[@B72]\].

Anti CD20 monoclonal antibody-rituximab
---------------------------------------

Rituximab is a monoclonal antibody directed against the CD20 antigen. It was initially developed and approved as a targeted agent for the treatment of CD20-positive non-Hodgkin lymphoma. In this setting, rituximab is mostly used in combination with chemotherapy (e. g. CHOP). Apart from the use of rituximab in oncology, its use has been extended to the treatment of refractory autoimmune diseases (e. g. rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura among others).

The application of rituximab in combination with or shortly before/after radiotherapy of non-Hodgkin lymphoma has been prospectively studied \[[@B73]-[@B75]\]. So far no significant additional toxicities have been reported. All side effects seen in the trials have been attributed to the individual therapeutic modalities respectively \[[@B76]\]. Thus, at present the combination of rituximab with radiation does not seem to harbour any relevant risks.

### Small molecules/tyrosine-kinase inhibitors (TKI\'s)

TKI\'s are small molecules able to pass the cell membrane and to inhibit intracellular tyrosine kinases of several growth factor receptors. Relevant examples are sunitinib, sorafenib, erlotinib or gefitinib. At present, TKI are used for diverse cancer entities and various clinical settings. Key indications are: Metastasized lung cancer/renal cell cancer/pancreatic cancer, locally advanced and metastatic breast cancer as well as hepatocellular carcinoma.

Up to now, no TKI has been approved for the simultaneous use with radiotherapy.

All toxicity data on combined toxicity are limited to case reports or studies with small numbers of patients. The clinical indications and the most common adverse effects of clinically used TKI\'s are summarized in Table [3](#T3){ref-type="table"}.

###### 

Studies on small molecules.

  Substance                     Author(s)                               Year   Study type                    N    tumour                         RT dose/ChTx/technique                                                                        Toxicity
  ----------------------------- --------------------------------------- ------ ----------------------------- ---- ------------------------------ --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sunitinib                     Chi et al. \[[@B153]\]                  2010   Phase II                      23   HCC                            52.5 (15 Fx) IMRT/3D-CT                                                                       9% grade III upper GI bleeding, 4% hepatitis grade III/4% grade III pancreatitis, 26% grade III + IV thrombopenia, 4% grade III leukopenia
                                Stähler et al. \[[@B154]\]              2010   Prospective, non-randomized   22   RCC (all sites)                Median 40 Gy (median 8 Fx)                                                                    5% grade IV hypertension, 14% grade III + IV nausea
                                Kao et al. \[[@B80]\]                   2009   Phase I                       21   Oligometastases                40-50 Gy (10 Fx)                                                                              62% grade III + IV lymphopenia, 19% grade III neutropenia, 14% grade III + IV thrombopenia, 5% grade III rectal bleeding
                                Hui et al. \[[@B155]\]                  2010   Phase II                      13   Nasopharyngeal carcinoma       Sunitinib [after]{.ul}RT (60-70 Gy) and multiple Chx                                          15% fatal hemorrhages, 31% Grade IV hemorrhages, (among other toxicities)
  sorafenib                     Peters et al. \[[@B77]\]                2008   Case study                    1    RCC                            8 Gy single dose                                                                              Grade V bowel perforation (stopped two days before, three days later recommenced)
  lapatinib                     Harrington et al. \[[@B156]\]           2009   Phase I                       31   LA-HNSCC                       66-70 Gy + CisPt                                                                              35% grade III mucositis, 19% grade III dermatitis, 13% grade III + IV lymphopenia, 6% grade III neutropenia
  gefitinib                     Cohen et al. \[[@B157]\]                2010   Phase I                       69   LA-HNSCC                       IC Carbo/Tax, hydroxyurea + 5-FU, 2 × 1.5 Gy/d                                                29% grade III + IV neutropenia, 86% grade III + IV mucositis, 33% grade III + IV dermatitis, 3% grade V infections, 17% grade III + IV infections, 4% grade III rash, 3% grade III neurotoxicity
                                Pollack et al. \[[@B158]\]              2011   Phase II                      43   Brainstem glioma in children   55,8 Gy                                                                                       Grade III+IV: lymphopenia (21%), neutropenia (2%), GI (12%), infection (7%), n, pulmonary (5%), renal, skin (2%), metabolic (2%), intratumoral hemorrhage: 7%.
                                Valentini et al. \[[@B159]\]            2008   Phase I/II                    41   Rectal cancer                  45 Gy + 5.4 Gy + 5-FU                                                                         20% grade III + IV GI toxicity, 15% grade III + IV skin toxicity, 39% grade III + IV hepatic toxicity, 10% grade III + IV GU toxicity, 7% other toxicities grade III + IV
                                Wang et al. \[[@B160]\]                 2011   Prospective                   26   Stage III/IV NSCLC             Median 70 Gy                                                                                  Grade IV leukopenia 4%, grade IV thrombopenia 8%, grade III esophagitis 4%, grade III pneumonitis 4%
                                Zhang et al. \[[@B161]\]                2009   Phase I                       24   NSCLC                          54-60 Gy                                                                                      4% grade III nausea
                                Chen et al. \[[@B162]\]                 2007   Phase I                       23   HNSCC                          Up to 72 Gy                                                                                   13% grade III dermatitis, 57% grade III + IV mucositis, 39% grade III + IV dysphagia, 17% grade III + IV diarrhea, 30% grade III + IV neutropenia, 9% grade III + IV anemia, 4% grade IV tumour hemorrhage, 4% grade III GI bleeding
                                Maurel et al. \[[@B163]\]               2006   Phase I                       18   Pancreatic cancer              45 Gy                                                                                         No DLT, 11% grade III + IV neutropenia, 6% anemia grade III
                                Czito et al. \[[@B164]\]                2006   Phase I                       16   Pancreatic + rectal cancer     50.4 Gy (1.8 Gy) + capecitabine                                                               31% grade III + IV diarrhea
                                Center et al. \[[@B165]\]               2010   Phase I                       16   NSCLC                          70 Gy 3D-CT + docetaxel                                                                       27% grade III + IV hematotoxicity, 27% grade III + IV esophagitis, 20% grade III + IV pulmonary toxicity
                                Schwer et al. \[[@B166]\]               2008   Phase I                       15   Malignant glioma               SRS 18-36 Gy                                                                                  No DLT, no grade \> II
                                Olsen et al. \[[@B167]\]                2009   Phase I                       12   Pancreatic cancer              50.4 Gy (1.8 Gy)                                                                              45% grade III nausea
  erlotinib                     Brown et al. \[[@B168]\]                2008   Phase I/II                    79   GBM                            60 Gy + TMZ                                                                                   18% grade III/IV rash, 16% grade III/IV fatigue, 24% grade III/IV thrombopenia, 4% grade III nausea, 8% grade III diarrhea, 28% grade III/IV leukopenia, 3% grade III anorexia, 18% grade III/IV neutropenia, 6% grade III anemia, 14% grade III lymphopenia, 1% grade V infection without neutropenia, 5% grade III infection without neutropenia, 6% grade III/IV dyspnea, 1% grade III/IV keratitis, 1% grade V pneumonitis, 6% grade III/IV pneumonitis
                                Prados et al. \[[@B169]\]               2009   Phase II                      65   GBM                            59.4 Gy/60 Gy + TMZ                                                                           43% grade III lymphopenia, 3% grade IV neutropenia, 2% grade IV thrombopenia, 8% grade III/IV fatigue, 2% grade III diarrhea, 6% grade III rash
                                Herchenhorn et al. \[[@B170]\]          2010   Phase I/II                    37   LA-HNSCC                       70 Gy + Cis                                                                                   No DLT
                                Choong et al. \[[@B171]\]               2008   Phase I                       34   NSCLC Stage III                66 Gy (2 Gy), Arm A: Erlotinib + Cis/Eto, Arm B: Induction Carbo/Tax, Carbo/Tax + Erlotinib   41% grade III + IV WBC, 32% grade III + IV neutropenia, 21% grade III + IV thrombopenia, 26% grade III + IV esophagitis, 3% grade III + IV vomiting, 6% grade III + IV diarrhea, 3% grade III/IV pneumonitis/ototoxicity
                                Peereboom et al. \[[@B172]\]            2010   Phase II                      27   GBM                            60 Gy + TMZ                                                                                   7% grade V febrile neutropenia, 4% grade V sepsis without neutropenia, 4% grade V PCP, a pt grade III neutropenia, 15% grade III neutropenia, 30% grade III + IV thrombopenia, 56% pts grade III lymphopenia, 15% grade III + IV anemia, 7% grade III fatigue
                                Chang et al. \[[@B173]\]                2011   Retrospective                 25   NSCLC                          40-50 Gy                                                                                      4% grade III rash, 4% grade III diarrhea/esophagitis/anemia, 8% grade III neutropenia/thrombopenia, 8% grade V pneumonitis, 4% grade III pneumonitis
                                Li et al. \[[@B174]\]                   2010   Phase II                      24   LA esophageal cancer           60 Gy + Carbo/Tax                                                                             17% ≥ grade III leukopenia, 8% thrombopenia ≥ grade III
                                Broniscer et al. \[[@B175]\]            2009   Phase I                       23   GBM                            54-59.4 Gy                                                                                    39% grade III + IV lymphopenia, 4% grade III rash, 4% grade III diarrhea
                                Robertson et al. \[[@B176]\]            2009   Phase I                       22   Pancreatic cancer              Gem weekly, 30-38 Gy                                                                          5% grade III vomiting/fatigue/nausea, 5% grade III vomiting/diarrhea/nausea, 9% grade IV fatigue
                                Duffy et al. \[[@B177]\]                2008   Phase I                       20   Pancreatic cancer              50.4 Gy + Gem                                                                                 100% grade III lymphopenia, 25% grade III thrombopenia, 30% grade III neutropenia, 5% grade IV neutropenia, 10% grade III anemia, 5% grade III fatigue, 15% grade III diarrhea, 10% grade III rash
                                Krishnan et al. \[[@B178]\]             2006   Phase I                       20   GBM                            60 Gy                                                                                         15% grade III stomatitis, 5% grade III fatigue/diarrhea
                                Iannitti et al. \[[@B179]\]             2005   Phase I                       17   LA Pancreatic cancer           50.4 Gy + Tax/Gem                                                                             6% grade III nausea/fatigue/rash/small bowel stricture/thrombopenia (each), 18% grade III dehydration/thrombosis, 12% grade III diarrhea/hypersensitivity, 6% grade IV neutropenia
                                Nogueira-Rodrigues et al. \[[@B180]\]   2008   Phase I                       15   LA cervical cancer             45 Gy + brachyTx + CisPt                                                                      7% grade IV hepatotoxicity, 7% grade III dermatitis, 20% III diarrhea, 13% grade III rash
                                Arias de la Vega et al. \[[@B181]\]     2011   Phase I                       13   LA-HNSCC                       63 Gy + Cis adjuvant                                                                          Grade III/IV: Mucositis 54%, Asthenia 15%, skin 23%, diarrhea 15%.
                                Lind et al. \[[@B182]\]                 2009   Phase I                       11   NSCLC, brain metastases        WBRT (30 Gy)                                                                                  9% grade III rash/fatigue
                                Dobelbower et al. \[[@B183]\]           2006   Phase I                       11   Esophageal cancer              50.4 Gy + 5-FU                                                                                36% pts grade III + IV leukopenia, 9% grade III anemia, 9% grade III thrombopenia, 18% grade III + IV neutropenia, 27% grade III dehydration, 9% grade III nausea, 9% grade III/9% grade IV esophagitis
                                Silvano et al. \[[@B82]\]               2008   Case report                   1    NSCLC                          2 × 8 Gy                                                                                      Death caused by fatal diarrhea
                                Huang et al. \[[@B184]\]                2008   Case study                    1    NSCLC                          WBRT 37.5 Gy                                                                                  Death caused by exacerbated radiodermatitis and subdural hemorrhage
  mTOR inhibitors (Sirolimus)   Sarkaria et al. \[[@B185]\]             2007   Phase I                       7    NSCLC                          60 Gy + CisPt weekly                                                                          14% grade III dysphagia, esophagitis, febrile neutropenia, pneumonia
                                Bourgier et al. \[[@B186]\]             2011   Case reports                  3    Breast/prostate/ovary cancer   45 Gy/70 Gy, later                                                                            Gastrointestinal radiation recall syndrome with everolimus/temsirolimus

N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, HCC-hepatocellular carcinoma, RCC-renal cell cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis, Fx-fractions, SRS-stereotactic radiosurgery, DLT-dose limiting toxicity, LA-locally advanced, Gem-gemcitabine, Tax-Taxol (paclitaxel), Tx-therapy, TMZ-temozolomide, PCP-Pneumocystis pneumonia, Cis-cisplatin, Eto-etoposide,

When using sunitinib or sorafenib alone, mainly diarrhea, hypertension, fatigue, hand-foot syndrome, bleeding and hematotoxicity may occur as side effects. Concerning combined use with radiotherapy, one case report described a lethal small bowel perforation after 1x 8 Gy in a palliative setting, sorafenib had been stopped 2 days before and three days after radiotherapeutic treatment \[[@B77]\]. In another case, a lethal bronchial fistula occurred after radiation of the mediastinum \[[@B78]\]; as this phenomenon has been observed after sunitinib alone \[[@B79]\] no definite causality can be deduced. Furthermore, elevated bone-marrow toxicity was observed if large volumes of bones or liver were radiated; a phase I study concluded to avoid the combination with sunitinib when radiating volumes of more than 6 ccm of the liver. A dose reduction of sunitinib was advised for the following phase II study \[[@B80]\].

In patients with cerebral metastases increased intracerebral bleeding has been reported, this appears to happen with or without radiotherapy \[[@B81]\].

Concerning the simultaneous use of gefitinib/erlotinib and radiotherapy one case of fatal diarrhea after combining erlotinib with RT in the abdomen (2x8 Gy, q1w) has been reported \[[@B82]\]. And again, in patients with cerebral metastases increased intracerebral bleeding has been reported, however, this appears to happen with or without radiotherapy \[[@B83]\].

As long as no reliable data concerning the safety of the combination of TKI\'s and radiotherapy are available, such therapies should be used very carefully, especially if the above reported organs received relevant radiation doses. So far it is unclear if the increased intracerebral bleeding rates are induced by the combined treatment or by the drug alone. However, because of the severity of this adverse effect, special caution is warranted for combined treatment schedules. The same applies for tumours that tend to bleed outside of the brain. Radiotherapy in the abdomen or the pelvis together with TKI\'s might lead to an increased toxicity, including the occurrence of ulcera and bleeding.

### mTOR inhibitors

According to pre-clinical data, an improvement of tumour growth by simultaneous administration of temsirolimus with radiotherapy seems possible \[[@B84]-[@B86]\]. However, the only study on long-term local tumor control revealed no beneficial effect regarding the combined treatment \[[@B84]\]. Preclinical data show an inhibition of vascular growth when combining everolimus with radiation, however a direct radio-sensitizing effect could not be consistently shown \[[@B85],[@B86]\]. A recent study \[[@B87]\] showed evidence for a suppressed dsDNA break repair by everolimus.

Concerning toxicity, there is one phase I study using temsirolimus with topotecan in recurrent gynaecological malignancies \[[@B88]\]. Dose-limiting toxicity of this combination was myelo-suppression. Although this toxicity cannot be attributed to temsirolimus, we advise caution when combining mTOR-inhibitors with concomitant or sequential radiotherapy, especially if large volumes of bone are in-field as the latter is already known to potentially cause myelo-suppression.

Nevertheless there are no sufficient clinical data to adequately judge the risks and potential benefits of a combined use of mTOR-inhibitors with radiotherapy. As long as this is the case, it can be assumed that-similar to anti-angiogenic substances-the combinational use may lead to wound healing deficits, increased bleeding and thrombosis.

Lenalidomide/thalidomide
------------------------

Data on available studies combining radiotherapy and lenalidomide or thalidomide treatment are shown in Table [4](#T4){ref-type="table"}. Thalidomide was initially used and approved as sedative drug until the early 1960s when it became clear that the intake of \"Contergan\" during pregnancy could lead to severe deformities. It was only in the late 1990s that thalidomide was rediscovered for its anti-angiogenic properties in cancer therapy \[[@B89]\]. Thalidomide is clinically used in the treatment of multiple myeloma; other areas of possible clinical use and ongoing clinical trials include leprosy, erythema nodosum leprosum and myelodysplastic syndrome.

###### 

Studies on thalidomide and derivatives.

  Substance      Author(s)                     Year   Study type    N                      tumour                      RT dose/ChTx/technique                Toxicity
  -------------- ----------------------------- ------ ------------- ---------------------- --------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Thalidomide    Knisely et al. \[[@B93]\]     2008   Phase III     332 (90 thalidomide)   Brain metastases            37,5 Gy (2,5 Gy)                      53% interruptions because of side-effects
                 Chang et al. \[[@B187]\]      2004   Phase II      67                     GBM                         60 Gy (2 Gy), TMZ concomitant         10% grade III + IV neutropenia, 1% grade V; 16% grade III + IV thrombopenia, 9% grade III + IV rash, 1% grade III constipation, 9% grade III fatigue
                 Atkins et al. \[[@B188]\]     2008   Phase II      39                     CNS metastases (melanoma)   30 Gy (3 Gy) WBRT + TMZ concomitant   10% grade III + IV + V thrombosis, 5% grade III + IV + V myelosuppression, 8% grade III + IV + V cardiac events
                 Ch\'ang et al. \[[@B189]\]    2011   Phase II      24                     HCC                         50 Gy (2 Gy)                          54% rash, 38% somnolence, 33% constipation
                 Turner et al. \[[@B97]\]      2007   Phase II      13                     Brainstem glioma + GBM      55.8 Gy (1.8 Gy)                      8% grade IV DVT, ≥ 15% grade III leukopenia/motoneuropathy/constipation
  Lenalidomide   Drappatz et al. \[[@B101]\]   2009   Pilot study   23                     GBM                         60 Gy (2 Gy)                          4% grade IV pneumonitis/hypoxia, 9% grade III nausea, 4% grade IV pulmonary embolism, 4% grade III pneumonia

N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, LA-HNSCC-locally advanced head-and-neck cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis

The most common side effects of thalidomide-besides somnolence-are thromboembolic events as well as peripheral polyneuropathy.

In vitro studies with cells of squamous cell carcinoma and of multiple myeloma showed no evidence for any radio-sensitizing quality of thalidomide. However, a radio-sensitizing effect has been observed in normal hematopoietic bone marrow \[[@B90]\]. Experiments in mice showed thalidomide induced tumour re-oxygenation pointing to a possible radio-sensitizing effect in vivo \[[@B91]\]. Experiments in rats indicate that thalidomide might be protective against radiation-induced proctitis when given 7 days after a single-RT \[[@B92]\].

In humans, thalidomide has been tested in combination with radiotherapy in phase I-III studies. Most data exist for radiation of the CNS combined with the administration of thalidomide.

The largest study so far was conducted by Knisely and co-workers \[[@B93]\]. In this phase III study 183 patients with multiple cerebral metastases were randomized for palliative WBRT (37,5 Gy in 15 fx) vs. WBRT (same dose and number of fractions) with thalidomide. In this study, only the known side effects of thalidomide occurred in the usual frequency. Hints to a possible interaction with radiotherapy have not been reported. Nearly half of the patients discontinued the study in the thalidomide arm due to side effects. The major limiting side effect was somnolence \[[@B93]\].

In malignant glioma, thalidomide was used in combination with radiotherapy or radiotherapy plus temozolomide in primary or recurrent settings \[[@B94]\]. Intratumoural bleeding and thromboembolic complications have been reported. However, the rate of complications was not higher than the reported rates for thalidomide alone \[[@B95]-[@B97]\].

Other studies, combining radiotherapy of soft tissue/bone metastasis as well as pelvic tumours with thalidomide simultaneously or sequentially revealed no evidence for increased risks of acute or late side effects \[[@B99]\].

However, a single study using radiotherapy (66 Gy in 33 fx) combined with vinorelbine and thalidomide in NSCLC stage III was abrogated after 10 patients due to side effects (thromboembolic, 1 bradycardia II°) \[[@B100]\]. As in this study only known side effects of thalidomide occurred, it still remains unclear whether radiation including the lung or the heart leads to increased side effects when combined with thalidomide.

Altogether the combination of thalidomide with simultaneous or sequential RT does not seem to be critical. Only in cases when large volumes of the heart or the lung are exposed, a certain level of cautiousness should be advised.

### Lenalidomide

Lenalidomide is a derivative of thalidomide. Thus, the anti-angiogenic effect and the adverse effects are to a large extent similar to thalidomide. However, it largely lacks the sedative side effect, making it better tolerable for patients. Leukopenia and thrombocytopenia have also been reported.

In Europe and the US it is only approved in combination with dexamethasone for the treatment of multiple myeloma as 2nd line therapy. There is only very limited data regarding the combination of lenalidomide and radiotherapy. A single phase I trial \[[@B101]\] in glioblastoma used lenalidomide with RT (60 Gy, 30 fx). Thromboembolic events, pneumonitis and elevation of transaminases have been reported. The maximal tolerable dose was reported to be 15 mg/m^2^, corresponding to the respective dose for monotherapy. Being chemically similar to thalidomide and having a similar profile of side effects, one can indirectly assume a similar pattern of interaction with radiation.

### Imatinib

Imatinib is a tyrosine-kinase inhibitor (TKI) of bcr-abl, PDGFR alpha/beta and c-kit. The first successful clinical application of imatinib was in chronic myeloid leukaemia as the bcr-abl-fusion gene plays a crucial role in this disease. As GIS-tumours display a high number of c-kit-mutations, they are currently also treated with imatinib. Imatinib alone is usually well tolerated. Known adverse effects are diarrhea, nausea, vomiting, erythema, edema or the increase of transaminases; leukopenia or thrombopenia usually occur only in leukemic diseases. Grade III-IV toxicity is reported in fewer than 10% of the patients.

Several in vitro experiments showed a putative radio-sensitizing effect of imatinib \[[@B102]\]. Additionally it has been shown, that the proliferation of fibroblasts can be slowed down in vitro by imatinib \[[@B103]\]. This leads to speculations about a potential protective effect of imatinib with regard to radiation-induced fibrosis. Three in vivo experiments support this hypothesis \[[@B104]-[@B106]\].

Regarding the clinical use of radiotherapy and imatinib only limited data is available. Imatinib has been used in recurrent glioma after radiotherapy (one 112-patient-trial with imatinib alone after radiotherapy and three 30-40-patient trials in combination with hydroxyurea). Unexpected adverse effects pointing to an increased toxic profile for the sequential use have not been reported \[[@B107]-[@B110]\]. In another trial, 27 patients have been treated with imatinib after radiotherapy in prostate cancer without unexpected side effects \[[@B111]\].

There is only one clinical phase I study regarding the simultaneous application of imatinib to radiotherapy (55.8 Gy in 21 fx) in children with brainstem-tumours. Retrospectively compared to a similar collective, subclinical bleeding seemed increased, but no other unexpected toxicities have been reported \[[@B112]\]. Additionally, there are two case reports for the combinational approach \[[@B113],[@B114]\]. Again, in both cases no unexpected side effects have been reported.

Altogether, sequential application of imatinib with radiotherapy might not bear an increased risk for adverse effects. For the simultaneous application the limited amount of data does not allow a valid judgement about potentially increased side effects.

Discussion
==========

Radiotherapy combined with molecular targeted agents may be associated with unforeseen yet specific toxicities. Based on putative interactions of radiotherapy and the given agent with the targeted signalling cascade, any interactions may not only interfere with any anti-tumour efficacy but may also increase side effects. On the other hand, also radio-protective effects for the tumour are possible if new combined treatment schedules are used. Examples are cetuximab in multimodal radio-chemotherapy regimens for rectal cancer \[[@B115]-[@B119]\] or erythropoietin, which was thought to increase the haemoglobin level in head-and-neck cancer patients, but decreased survival most likely due to EPO-receptors on the cancer cells which were not known as a proliferative factor for tumours before \[[@B120],[@B121]\].

However, there are still clinical situations where patients may benefit from the application of a targeted drug in combination with radiotherapy outside approved treatment schedules or clinical trials. The best example is a palliative systemic treatment for disseminated metastases and at the same time an indication for palliative or symptomatic radiotherapy of a single region. In this case, interruption of the systemic treatment may lead to systemic progression under radiotherapy. The present work aims to provide a helpful tool for clinical treatment decisions in such situations.

At present, only limited data is available on the interactions of targeted agents and radiotherapy. Data on toxicity are mostly derived from small case series, retrospective analyses or at best cohort and few randomized studies. For most substances, mild complications are reported-however, rarely exceptional fatal complications have been documented.

Overall, for any of the drugs mentioned here indications for a combination with radiotherapy have to be made cautiously (is a sequential treatment possible?). Furthermore, patients have to be questioned very specifically regarding the intake of targeted drugs. Frequently patients have been advised that these drugs are not \"classical cytostatic drugs\". Thus patients often do not self-report intake of targeted drugs when counselled for radiotherapy.

Simultaneous applications of targeted drugs during radiotherapy in non-established schedules should be an exception and reserved for those patients where the systemic tumour situation mandates rapid treatment. Whenever possible, large volume radiotherapy plus targeted drugs should be avoided. These remarks are especially important for hypo-fractionated regimens where high toxicities have been observed (in part with fatal consequences).

In conclusion, molecular targeted agents should only very cautiously in combination with radiotherapy. A meticulous and careful balancing of benefits and risks of increased toxicity is advised.

Abbreviation
============

CNS: central nervous system; CT: chemotherapy; DFS: disease-free survival; EBRT: external beam radiotherapy; EGFRi: epidermal growth factor receptor inhibitor; IGRT: image-guided radiotherapy; KPS: Karnofsky Performance Status; mo: months; mPFS: median progression-free survival; MST: median survival time; MTD: maximum tolerated dose; mTOR: mammalian target of rapamycin.; mTTP: median time to progression; NTD: normalized total dose; OS: overall survival; PFS-6/-12: progression-free survival rate at 6/12 months; pt(s): patient(s); PTEN: phosphatase and tensin homolog deleted on Chromosome 10; QOL: quality of life; RCHT: radio-chemotherapy; RT: radiotherapy; VEGF-R: vascular endothelial growth factor receptor; WBRT: whole brain radiotherapy; wk: week.
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